As of Tuesday, December 16, Alto Neuroscience, Inc.’s ANRO share price has dipped by 6.34%, which has investors questioning ...

These deals radically reshaped the biopharma world, either by one vaccine rival absorbing another, a Big Pharma doubling down ...

Zachary Contreras highlighted strategies discussed at AMCP Nexus for improving timely access to monoclonal migraine receptor ...

Flow Neuroscience has secured FDA approval for its at-home brain stimulation device, the FL-100 wearable device, as a ...

Adding lumateperone (Caplyta; Johnson & Johnson) to ongoing antidepressant therapy (ADT) significantly improved depression severity in adults with major depressive disorder (MDD) who had not responded ...

Propelled by a flurry of dealmaking late in the year, 2025 M&A ended on a strong note, with high activity expected to ...

Ireland’s gross domestic product (GDP) fell slightly during the period July to September, following a surge earlier this year ...

Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA-cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States.

Detailed price information for SPDR S&P Midcap International (MDD-A) from The Globe and Mail including charting and trades.

Xenon Pharmaceuticals (XENE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Detailed price information for SPDR S&P Midcap International (MDD-A) from The Globe and Mail including charting and trades.

Praxis Precision Medicines, Inc. soars after study success and pipeline wins. Explore key milestones, projections, and ...